Primer sklerozan kolanjit - Hacettepe Üniversitesi Tıp Fakültesi
Primer sklerozan kolanjit - Hacettepe Üniversitesi Tıp Fakültesi
Primer sklerozan kolanjit - Hacettepe Üniversitesi Tıp Fakültesi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Elsürer ve Bayraktar<br />
Uygun yapılmayan cerrahi girişimler gelecekte yapılacak<br />
karaciğer transplantasyonunda komplikasyonlara<br />
neden olabilmektedir [12].<br />
İleri evre PSK’da karaciğer transplantasyonu etkili<br />
olan tek tedavi yöntemidir. Transplantasyon endikasyonları<br />
arasında varislere veya portal gastropatiye bağlı<br />
kanama, dirençli asit ve/veya bakteriyel peritonit, tekrarlayan<br />
bakteriyel <strong>kolanjit</strong>, progresif kas atrofisi ve hepatik<br />
ensefalopati sayılabilir. Transplantasyon sonrası<br />
üç yıllık sağkalım süresi %85-90 arasındadır. Transplante<br />
edilen safra kanallarında strüktür gelişimi sık karşılaşılan<br />
bir problemdir. Transplantasyon sonrası tekrar<br />
PSK gelişme sıklığı ve zamanı tartışmalıdır, ancak olguların<br />
ortalama %10-20’sinde PSK gelişmektedir [2].<br />
Kaynaklar<br />
1. Farrell RJ, Kelly CP. Sclerosing cholangitis and recurrent<br />
pyogenic cholangitis. In: Feldman M, Friedman LS, Sleisenger<br />
MH (eds). Sleisenger & Fordtran’s gastrointestinal and<br />
liver disease pathophysiology/diagnosis/management. Vol<br />
2. 7th ed. China, 2002; 1131-47.<br />
2. Lee YM, Kaplan MM, and the Practice Guideline Committee<br />
of the ACG. Management of primary sclerosing cholangitis.<br />
Am J Gastroenterol 2002; 97:528-34.<br />
3. Textor J, Flacke S, Pauleit D, et al. Three-dimensional magnetic<br />
resonance cholangiopancreatography with respiratory<br />
triggering in the diagnosis of primary sclerosing cholangitis:<br />
comparison with endoscopic retrograde cholangiography.<br />
Endoscopy 2002; 43:984-90.<br />
4. Chapman RG. Small duct primary sclerosing cholangitis. J<br />
Hepatol 2002; 36:692-4.<br />
134<br />
5. Bayraktar Y, Arslan S, Sağlam F, Uzunalimoğlu B, Kayhan B.<br />
What is the association of primary sclerosing cholangitis<br />
with sex and inflammatory bowel disease in Turkish patients?<br />
Hepatogastroenterology 1998; 45:2064-72.<br />
6. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct sclerosing<br />
cholangitis: a long-term follow-up study. Hepatology<br />
2002; 35:1494-500.<br />
7. Ichimura T, Kondo S, Ambo Y, et al. Primary sclerosing cholangitis<br />
associated with autoimmune pancreatitis. Hepatogastroenterology<br />
2002; 49:1221-4.<br />
8. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma<br />
in primary sclerosing cholangitis: risk factors and clinical<br />
presentation. Scand J Gastroenterol 2002; 37:1205-11.<br />
9. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic<br />
malignancies in primary sclerosing cholangitis. J Hepatol<br />
2002; 36:321-7.<br />
10. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic<br />
liver disease: mechanisms of action and therapeutic<br />
use revisited. Hepatology 2002; 36:525-31.<br />
11. Angulo P, MacCarty RL, Slyvestre PB, Jorgensen RA, Weisner<br />
RH, Larusso NA. Prifenidone in the treatment of primary<br />
sclerosing cholangitis. Dig Dis Sci 2002; 47:157-61.<br />
12. Holtmeier J, Leuschner U. Medical treatment of primary<br />
sclerosing cholangitis. Digestion 2001; 64:137-50.<br />
13. Kita R, Kita-Sasai Y, Hanaoka I, et al. Beneficial effect of bezafibrate<br />
on primary sclerosing cholangitis (three case reports).<br />
Am J Gastroenterol 2002; 97:1849-51.<br />
14. Stiel A, Rudolp G, Klöters-Plachky P, Sauer P, Walker S. Development<br />
of dominant bile duct stenoses in patients with<br />
primary sclerosing cholangitis treated with ursodeoxycholic<br />
acid: outcome after endoscopic treatment. J Hepatol<br />
2002; 36:151-6.<br />
H ACETTEPE T IP D ERG‹S‹
Change language